{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', '9.3.', 'Randomization and Study Drug Blinding', '9.3.1.', 'Blinding', 'This is a double-blind study throughout both Parts 1 and 2. As such, study drug assignment will', 'be blinded to the Investigator, study staff, study subjects, and clinical research organization staff.', 'Part 3 will be open-label. No blinding will be used.', 'During Part 1, Sponsor employee(s) will also be blinded to the treatment allocation of individual', 'subjects, with the exception of Sponsor staff responsible for managing clinical supplies.', 'Employees who are not blinded to drug assignment will have no access to any other subject-level', 'information for the duration of the study. Sponsor employees interacting with sites will remain', 'blinded for Part 2 of the study, however, unblinding of these staff may occur out of necessity', 'during document preparation for regulatory filings of the study.', 'The bioanalytical laboratory performing BCX7353 plasma concentration analysis will be given a', 'copy of the randomization scheme.', 'Information on unblinding in the event of an SAE is provided in Section 12.1.9.', '9.3.2.', 'Randomization', 'Subjects will be randomized via interactive (web or voice) response system (IXRS). Details on', 'the processes to be followed for randomization will be provided in a separate manual.', '9.3.2.1.', 'Part 1 Randomization', 'Approximately 96 subjects will be randomized in a 1:1:1 (active:active:placebo) ratio to 1 of the', 'following treatments in Part 1:', 'Group 1: BCX7353 110 mg administered orally QD for 24 weeks', 'Group 2: BCX7353 150 mg administered orally QD for 24 weeks', 'Group 3: Placebo administered orally QD for 24 weeks', 'Randomization will proceed in accordance with a computer-generated randomization schedule', 'prepared by a nonstudy statistician. There will be a separate randomization schedule for main', 'study and substudy subjects (adult and adolescent subjects, respectively).', 'Sites will randomize eligible subjects in the IXRS, preferably after all baseline assessments to', 'reconfirm eligibility have been completed.', 'If required by site procedures (ie, dispensing of randomized study drug must occur through a', 'pharmacy), the subject may be randomized on the business day prior to the planned baseline', 'visit. The Sponsor may require review of screening data prior to randomizing a subject', '(eg, concomitant medications); any requirements will be provided to the site separately.', 'Enrollment into treatment groups will be stratified by the baseline HAE attack rate', '(>2 attacks/month VS. < 2 attacks/month). The baseline attack rate must be provided during', 'randomization and is calculated by:', '(The number of HAE attacks meeting the criteria of an HAE attack below from the', 'Screening visit through the time of randomization X 28) divided by the number of days', '47']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', 'during the timeframe from the Screening visit through randomization, rounded up to', '2 decimal places', 'HAE attacks to be utilized in calculation of the baseline attack rate must meet the following', 'criteria:', 'The attacks must be unique, which is defined as an attack that does not begin within', '48 hours of the end of a previous attack.', 'The attacks must have either been treated, required medical attention or be', 'documented to cause functional impairment based on subject entry in the diary.', 'Functional impairment is defined as the subject being unable to perform their daily', 'activities without restriction (ie, subject records that they are at least slightly', 'restricted in their daily activities during their HAE attack).', 'The attacks must include symptoms of swelling. Symptoms of swelling, in addition to', 'visible swelling, may also include symptoms in the oropharyngeal or abdominal', 'regions which are indicative of internal swelling.', 'The attacks must be confirmed by the Investigator to be HAE attacks. Subjects will', 'be contacted within 2 business days of the attack to discuss the attack, any queries on', 'the entered data in the e-diary, as applicable.', '9.3.2.2.', 'Part 2 Randomization', 'Sites will randomize subjects in the IXRS at the Week 24 visit for Part 2 study drug. Subjects', 'who received active BCX7353 in Part 1 of the study (Treatment Groups 1 and 2) will continue to', 'receive the same dosing regimen in Part 2. Randomization for subjects randomized to placebo in', 'Part 1 (Treatment Group 3) will proceed in accordance with a computer-generated randomization', 'schedule prepared by a nonstudy statistician. These subjects will be randomized in a 1:1 ratio to', 'receive a 110 or 150 mg dose (see Figure 2). Sites will assign drug/randomize subjects in the', 'IXRS at the Week 24 visit for Part 2 study drug. Sites using a centralized pharmacy may', 'assign/drug randomize the subject the day prior to the Week 24 visit.', \"Based on the results of the current study's Part 1 analysis of better efficacy and no increase in\", 'safety risk at the 150 mg dose, all subjects will be transitioned to the 150 mg dose of BCX7353', 'on or after their Week 48 visit, regardless of their initial treatment allocation. Subjects will', 'receive 150 mg of BCX7353 in an open-label manner.', '48']\n\n###\n\n", "completion": "END"}